We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $404.05 · 21 analysts
US analyst rating / recommendation change.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Stored first · Google News · Yahoo Finance (English)
Elevance Health gains as Medicare sanctions risk abates (ELV) - Seeking Alpha
Elevance Health gains as Medicare sanctions risk abates (ELV) Seeking Alpha
Elevance Health (ELV) Makes Progress on Medicare Advantage Compl - GuruFocus
Elevance Health (ELV) Makes Progress on Medicare Advantage Compl GuruFocus
Elevance Health (ELV) Progresses on Medicare Advantage Enrollmen - GuruFocus
Elevance Health (ELV) Progresses on Medicare Advantage Enrollmen GuruFocus
CMS grants Elevance Health a reprieve from MA sanctions - Fierce Healthcare
CMS grants Elevance Health a reprieve from MA sanctions Fierce Healthcare
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 16. | After market close (AMC) | $6.2 | — | — | $48.63B | — | Scheduled |
| FY2026 Q1 | 2026. 04. 22. | Time TBD | — | $9.61 | — | — | $48.89B | Reported |
| FY2025 Q3 | 2025. 10. 21. | Time TBD | — | $23.81 | — | — | $131.57B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $19.44 | — | — | $86.46B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 27. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 23. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2026. 05. 20. | Mizuho | — | Maintain | Outperform → Outperform | — | Mizuho: Outperform |
| 2026. 05. 20. | Deutsche Bank | — | Upgrade | Hold → Buy | — | Deutsche Bank: Hold → Buy |
| 2026. 04. 29. | B of A Securities | — | Upgrade | Neutral → Buy | — | B of A Securities: Neutral → Buy |
| 2026. 04. 29. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.